Trials / Withdrawn
WithdrawnNCT02246816
A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001
A Phase 3, Open Label Extension Study for Subjects That Complete Study MP-101-CL-001
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Marathon Pharmaceuticals, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
MP-101 will be evaluated in this study to see if it is safe and tolerable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) | 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2018-02-01
- Completion
- 2018-02-01
- First posted
- 2014-09-23
- Last updated
- 2015-02-18
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02246816. Inclusion in this directory is not an endorsement.